
IOM: Cancer care is a 'system in crisis'
Rising costs of cancer care, and a lack of tools to manage quality of care, are highlighted in new Institute of Medicine report
Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis,
For the biopharma industry (whose input into this report is notably absent), there are two significant findings: because of the gap in elderly-specific research, the study committee recommends consideration of providing extended patent exclusivity to manufacturers who sponsor studies targeting the elderly (similar to the incentive currently available for pediatric treatment research); and that clinical practice guidelines (CPGs) or “pathways” for clinical care are much weaker than commonly understood. IOM had previously developed a set of standards for “trustworthiness” of CPGs. Arguably, the National Comprehensive Cancer Care Network (NCCN) guidelines are the best known CPGs, but
Related to this article








